Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6119560 | 0.91 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAPOLBGAATPSAB1 | |
| SCHEMBL16256877 | 0.86 | LMNA (0.58) | SMN1; SMN2LMNAPOLBGAATPSAB1 | |
| SCHEMBL11974037 | 0.86 | POLB (0.58) | SMN1; SMN2LMNAPOLBGAACHRM1 | |
| SCHEMBL725320 | 0.86 | LMNA (0.58) | SMN1; SMN2LMNAPOLBGAANOS3 | |
| SCHEMBL10576741 | 0.85 | GAA (0.64) | SMN1; SMN2POLBGAATPSAB1TPSD1 | |
| SCHEMBL7985579 | 0.84 | LMNA (0.56) | SMN1; SMN2LMNAPOLBGAANOS3 | |
| SCHEMBL3994255 | 0.84 | POLB (0.56) | SMN1; SMN2LMNAPOLBGAANOS3 | |
| SCHEMBL30510136 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAPOLBGAANOS3 | |
| SCHEMBL856302 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAPOLBGAANOS3 | |
| SCHEMBL7449135 | 0.83 | POLB (0.63) | SMN1; SMN2LMNAPOLBGAANOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105007-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-2560955-B1 | NOVEL BENZAMIDE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2016-06-29 | — | — | EP | disclosed |
| US-9221790-B2 | Benzamide derivatives | DONG-A PHARM. CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| CN-103547567-A | Hedgehog antagonists having zinc binding moieties | CURIS INC | 2014-01-29 | — | — | CN | disclosed |
| WO-2013066831-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130085160-A1 | NOVEL BENZAMIDE DERIVATIVES | DONG-A PHARM. CO., LTD. (KR) | 2013-04-04 | — | — | US | disclosed |
| EP-2560955-A2 | NOVEL BENZAMIDE DERIVATIVES | Dong-A Pharm.Co., Ltd. (KR) | 2013-02-27 | — | — | EP | disclosed |
| US-7026312-B2 | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20050215546-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-09-29 | — | — | US | disclosed |
| CN-1483028-A | Quinolinone derivatives as tyrosine kinase inhibitors | ϣ | 2004-03-17 | — | — | CN | disclosed |
| US-20030236282-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2003-12-25 | — | — | US | disclosed |
| EP-1326833-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | THE PROCTER GAMBLE CO. | 2002-07-25 | — | — | US | disclosed |
| WO-2002032869-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| US-6376514-B1 | PIPERIDINE-DERIVED COMPOUNDS CONTAINING A QUINOLYL GROUP THAT INHIBITS P-GLYCOPROTEIN TRANSPORT PROTEIN ACTIVITY; FOR TREATING CANCER AND OTHER DISEASES | THE PROCTER & GAMBLE CO. | 2002-04-23 | — | — | US | disclosed |
| EP-1171435-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061551-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | SMN1; SMN2 1951/4885LMNA 3644/4885POLB 1929/4885 |
| US-20020099215-A1 | Substituted heterocyclic compounds for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | SMN1; SMN2 2929/4885LMNA 3630/4885POLB 703/4885 |
| US-20130085160-A1 | NOVEL BENZAMIDE DERIVATIVES | HTR4, GPR4, HTR5A | SMN1; SMN2 1290/4885LMNA 4050/4885POLB 4794/4885 |
| US-20030236282-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | P2RX5, CALCRL, ADRA1D | SMN1; SMN2 2035/4885LMNA 492/4885POLB 2809/4885 |
| US-20050215546-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | P2RX3, P2RX5, P2RX2 | SMN1; SMN2 2489/4885LMNA 747/4885POLB 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.